Outset Medical (NASDAQ:OM) CFO Renee Gaeta Sells 4,543 Shares

Outset Medical, Inc. (NASDAQ:OM) CFO Renee Gaeta sold 4,543 shares of Outset Medical stock in a transaction on Monday, August 17th. The shares were sold at an average price of $4.39, for a total transaction of $19,943.77. Following the completion of the sale, the chief financial officer directly owned 180,840 shares of the company’s stock, valued at approximately $793,887.60. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Renee Gaeta also recently made the following trade(s):

• On Wednesday, June 3rd, Renee Gaeta sold 17,672 shares of Outset Medical stock. The stock was sold at an average price of $4.94, for a total transaction of $87,299.68.

Outset Medical Price Performance

OM stock opened at $4.18 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11. The company’s 50-day moving average is $4.57 and its 200-day moving average is $4.23. The stock has a market capitalization of $78.58 million, a PE ratio of -1.02 and a beta of 1.96. Outset Medical, Inc. has a 1 year low of $3.00 and a 1 year high of $16.16.

Outset Medical (NASDAQ:OM) last issued its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The firm had revenue of $31.64 million during the quarter, compared to the consensus estimate of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. Equities research analysts expect that Outset Medical, Inc. will post -3.8 EPS for the current fiscal year.

Institutional Trading of Outset Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OM. BML Capital Management LLC raised its stake in shares of Outset Medical by 250.2% in the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock worth $7,304,000 after purchasing an additional 1,359,021 shares during the last quarter. Alyeska Investment Group L.P. grew its holdings in Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after buying an additional 150,000 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in Outset Medical by 71.8% during the fourth quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock worth $2,078,000 after buying an additional 234,082 shares in the last quarter. Millennium Management LLC raised its position in Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after buying an additional 262,874 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Outset Medical by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 400,363 shares of the company’s stock valued at $1,486,000 after buying an additional 3,104 shares during the last quarter.

Wall Street Analysts Forecast Growth

OM has been the topic of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings upgraded shares of Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Outset Medical has a consensus rating of “Hold” and a consensus target price of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.